Steven J Greenberg1, Robert Zivadinov2, Peterkin Lee-Kwen3, Jitendra Sharma2, Margaret Planter3, Margaret Umhauer3, Norman Glenister4, Rohit Bakshi5. 1. Clinical Development, Neuroscience Global Pharmaceutical R&D, Abbvie Inc. 1 North Waukegan Road AP-31-1 North Chicago, IL 60064, USA. 2. Buffalo Neuroimaging Analysis Center, The Jacobs Neurological Institute, Department of Neurology, Buffalo General Hospital, Buffalo, NY, USA. 3. The Jacobs Neurological Institute, Department of Neurology, Buffalo General Hospital, Buffalo, NY, USA. 4. The Jacobs Neurological Institute, Department of Neurology, Buffalo General Hospital, Buffalo, NY, USA USA. 5. Jack, Sadie and David Breakstone Professor of Neurology and Radiology, Harvard Medical School, Director, Laboratory for Neuroimaging Research, Partners MS Center, Brigham and Women's Hospital, One Brookline Place, Suite 602, Brookline, MA 02445, USA.
Abstract
BACKGROUND:Patients with relapsing-remitting multiple sclerosis (RRMS) may experience breakthrough disease despite effective interferon beta (IFNβ) therapy. Fludarabine (FLU) is a chemotherapeutic agent used in lymphoproliferative disorders that may be synergistic when combined with immunomodulatory therapy to control active multiple sclerosis (MS). OBJECTIVE: The objective of this study was to explore the safety and tolerability of FLU versus monthly methylprednisolone (MP) in IFNβ-treated RRMS patients with breakthrough disease. Clinical and MRI effects of IFNβ-1a plus FLU were evaluated. METHODS:Eighteen patients with breakthrough disease [⩾2 relapses over the prior year and ⩾1.0-point increase in Expanded Disability Status Scale (EDSS) score sustained for ⩾3 months] after >1 year of IFNβ therapy were enrolled in this prospective, open-label, randomized, proof-of-concept, pilot study. Patients received intravenous (IV) MP 1 g daily for 3 days and then were randomized to receive 3 monthly IV infusions of FLU 25 mg/m(2) daily for 5 consecutive days (n = 10) or MP 1 g (n = 8). All patients maintained their intramuscular IFNβ-1a treatment throughout the study. Analyses explored safety signals and directional trends; this preliminary study was not powered to detect clinically meaningful differences. RESULTS: Both combination treatments were safe and well tolerated, with all adverse events mild. Patients treated with IFNβ-1a plus FLU had similar relapse rates, EDSS scores, and MS Functional Composite scores, but significantly less acute corticosteroid use for on-study relapses and better responses on some MRI outcomes, versus patients treated with IFNβ-1a plus MP. CONCLUSIONS: Further study of FLU for breakthrough disease in patients with RRMS is warranted.
RCT Entities:
BACKGROUND:Patients with relapsing-remitting multiple sclerosis (RRMS) may experience breakthrough disease despite effective interferon beta (IFNβ) therapy. Fludarabine (FLU) is a chemotherapeutic agent used in lymphoproliferative disorders that may be synergistic when combined with immunomodulatory therapy to control active multiple sclerosis (MS). OBJECTIVE: The objective of this study was to explore the safety and tolerability of FLUversus monthly methylprednisolone (MP) in IFNβ-treated RRMS patients with breakthrough disease. Clinical and MRI effects of IFNβ-1a plus FLU were evaluated. METHODS: Eighteen patients with breakthrough disease [⩾2 relapses over the prior year and ⩾1.0-point increase in Expanded Disability Status Scale (EDSS) score sustained for ⩾3 months] after >1 year of IFNβ therapy were enrolled in this prospective, open-label, randomized, proof-of-concept, pilot study. Patients received intravenous (IV) MP 1 g daily for 3 days and then were randomized to receive 3 monthly IV infusions of FLU 25 mg/m(2) daily for 5 consecutive days (n = 10) or MP 1 g (n = 8). All patients maintained their intramuscular IFNβ-1a treatment throughout the study. Analyses explored safety signals and directional trends; this preliminary study was not powered to detect clinically meaningful differences. RESULTS: Both combination treatments were safe and well tolerated, with all adverse events mild. Patients treated with IFNβ-1a plus FLU had similar relapse rates, EDSS scores, and MS Functional Composite scores, but significantly less acute corticosteroid use for on-study relapses and better responses on some MRI outcomes, versuspatients treated with IFNβ-1a plus MP. CONCLUSIONS: Further study of FLU for breakthrough disease in patients with RRMS is warranted.
Authors: Mads Ravnborg; Per Soelberg Sørensen; Magnus Andersson; Elisabeth G Celius; Peter J Jongen; Irina Elovaara; Emmanuel Bartholomé; Cris S Constantinescu; Karsten Beer; Ellen Garde; Bjørn Sperling Journal: Lancet Neurol Date: 2010-06-09 Impact factor: 44.182
Authors: Robert A Bermel; Xiaojun You; Pamela Foulds; Robert Hyde; Jack H Simon; Elizabeth Fisher; Richard A Rudick Journal: Ann Neurol Date: 2013-01 Impact factor: 10.422
Authors: L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham Journal: Ann Neurol Date: 1996-03 Impact factor: 10.422
Authors: Regina Berkovich; Rohit Bakshi; Lilyana Amezcua; Robert C Axtell; Steven Y Cen; Shahamat Tauhid; Mohit Neema; Lawrence Steinman Journal: Ther Adv Neurol Disord Date: 2016-10-19 Impact factor: 6.570